Implementation of a new algorithm for HRR gene mutation testing in patients with mPC through liquid biopsy integration
Patients with metastatic prostate cancer whose tumor tissue is unavailable or inadequate for molecular testing. • Written informed consent must be signed and dated by the patient and the investigator prior to inclusion.
Unable to provide written informed consent
Patients with metastatic prostate cancer
Case-only
Prospective
Not listed
Validation of an assay for homologous recombination repair (HRR) gene mutation testing using liquid biopsy
Validation of an assay for homologous recombination repair (HRR) gene mutation testing using liquid biopsy in patients with metastatic prostate cancer (mPC) whose tumor tissue is inadequate or unavailable for molecular testing.
Click on the lead sponsor to view all of their trials.
